{"entity":{"id":"tubulis","kind":"company","name":"Tubulis (Gilead)","aka":[],"tldr":"German ADC company whose NaPi2b ADC TUB-040 posted a 59% response rate in platinum-resistant ovarian cancer; Gilead bought it in May 2026 for $3.15B upfront and up to $1.85B in milestones.","summary":"Raised a record €344M Series C (October 2025) after TUB-040 phase 1/2a data at ESMO 2025 (59% ORR in platinum-resistant ovarian cancer; also lung adenocarcinoma). Gilead completed its acquisition on 21 May 2026, paying $3.15B upfront with up to $1.85B in contingent milestones; the acquisition also brought TUB-030, a 5T4-targeted ADC, and the team stays in Munich. Proprietary Tubutecan and P5 conjugation chemistries.","asOf":"2026-10-29","links":[{"label":"Gilead acquisition","url":"https://www.biospace.com/business/gilead-swallows-another-partner-paying-up-to-5-b-for-adc-specialist-tubulis"},{"label":"Gilead completes acquisition (May 2026)","url":"https://www.gilead.com/news/news-details/2026/gilead-sciences-completes-acquisition-of-tubulis-further-strengthening-oncology-portfolio"}],"tags":[],"related":[],"cancers":["ovarian","nsclc"],"sections":["adcs"],"technologies":["adc","site-specific-conjugation"],"targets":[],"drugs":[],"companies":["gilead"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06657222","nct07736937","nct06303505"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Freshened 29 October 2026: the Gilead acquisition, announced earlier with a second-quarter 2026 close expected, was confirmed complete in Gilead's release of 21 May 2026. The Series C figure was not re-checked in this pass."],"hq":"Munich","country":"DE","companyType":"biotech","website":"https://tubulis.com","stage":"acquired","investors":[],"funding":[{"round":"Acquisition","year":2026,"amountUsd":3150000000,"source":"https://www.gilead.com/news/news-details/2026/gilead-sciences-completes-acquisition-of-tubulis-further-strengthening-oncology-portfolio","note":"Upfront consideration on a cash-free, debt-free basis, plus up to 1.85 billion US dollars in contingent milestones; completed 21 May 2026"}],"acquiredBy":"gilead"},"route":"/companies/tubulis/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"site-specific-conjugation","kind":"technology","name":"Site-specific conjugation & linker chemistry","route":"/technologies/site-specific-conjugation/"}],"company":[{"id":"gilead","kind":"company","name":"Gilead Sciences (incl. Kite)","route":"/companies/gilead/"}],"trial":[{"id":"nct06303505","kind":"trial","name":"FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC","route":"/trials/nct06303505/"},{"id":"nct06657222","kind":"trial","name":"First in Human Study of TUB-030 in Patients With Advanced Solid Tumors","route":"/trials/nct06657222/"},{"id":"nct07736937","kind":"trial","name":"Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer","route":"/trials/nct07736937/"},{"id":"nct07806773","kind":"trial","name":"Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer","route":"/trials/nct07806773/"}]}}